Lu Yang

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 12

Top Topics

Chronic Myeloid Leukemia

Ejection Fraction

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

Thoracic cancer

Cancer medicine

Targeted oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Shuyang Zhang, Lu Yang, Yaning Yang, Guangjian Yang, Haiyan Xu, Xueliang Niu, Yan Wang
The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study. Cancer medicine (2023)
Yaning Yang, Xin Ai, Hai-Yan Xu, Guangjian Yang, Lu Yang, Xuezhi Hao, Ke Yang, Yuling Mi, Guizhen Wang, Shuyang Zhang, Siyu Lei, Yan Wang
Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice. Thoracic cancer 13 (23) (2022)
Shuyang Zhang, Lu Yang, Yaning Yang, Ying Xin, Yan Wang
An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer. Thoracic cancer 13 (23) (2022)
Shuyang Zhang, Huihui Yin, Jing Zhang, Lu Yang, Guangjian Yang, Jia Jia, Yuchen Jiao, Jianming Ying, Yan Wang
Novel genetic characteristics in low-grade fetal adenocarcinoma of the lung. Thoracic cancer 12 (20) (2021)
Hai-Yan Xu, Weihua Li, Guangjian Yang, Junling Li, Lu Yang, Fei Xu, Yaning Yang, Jianming Ying, Yan Wang
Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations. Targeted oncology 15 (3) (2021)
Yaning Yang, Haiyan Xu, Li Ma, Lu Yang, Guangjian Yang, Shuyang Zhang, Xin Ai, Shucai Zhang, Yan Wang
Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients. Cancer medicine 10 (23) (2021)
Lu Yang, Xuezhi Hao, Xingsheng Hu, Zhijie Wang, Ke Yang, Yuling Mi, Yaning Yang, Hai-Yan Xu, Guangjian Yang, Yan Wang
Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. Thoracic cancer 11 (12) (2020)
Hai-Yan Xu, Quan Zhang, Li Liang, Junling Li, Zhefeng Liu, Weihua Li, Lu Yang, Guangjian Yang, Fei Xu, Jianming Ying, Shucai Zhang, Yan Wang
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. Cancer medicine 9 (10) (2020)
Fei Xu, Guangjian Yang, Hai-Yan Xu, Lu Yang, Weini Qiu, Yan Wang
Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China. Thoracic cancer 11 (3) (2020)
Hai-Yan Xu, Guangjian Yang, Lu Yang, Yaning Yang, Di Ma, Junling Li, Xuezhi Hao, Puyuan Xing, Yan Wang
Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance. Thoracic cancer 10 (5) (2019)
Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study. Cancer medicine 8 (13) (2019)
Lu Yang, Sheng Yang, Yutao Liu, Junling Li, Xingsheng Hu, Yalei Wang, Yan Zhang, Yan Wang
Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial. Thoracic cancer 9 (6) (2018)